In a new update on Thursday, Pfizer and Biotech announced that its booster vaccine dose can protect people from all variants of COVID-19, including the new Delta variant. The company tweeted that the booster dose is showing “encouraging clinical trial data” when tried on a small number of participants as part of a study.
According to the company, the first two doses showed a high immune response against the new variant. The current study is focused on whether the booster dose will increase the immune response even further.
Advertisement
“While Pfizer and BioNTech believe a third dose has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant,” said Pfizer in an official statement.
“Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile”, the company further added.
As we continue to be led by the science, today we are providing an update on our comprehensive #COVID19 vaccine booster strategy in light of emerging data including data relating to the #DeltaVariant. https://t.co/P0XmAGrxlt pic.twitter.com/JZ5JIIKwHC
— Pfizer Inc. (@pfizer) July 8, 2021